Quick Answer
Celldex Therapeutics, Inc. reported Total Assets of $582.98 million for fiscal year 2025.
Celldex Therapeutics, Inc. Total Assets — Annual History
| Fiscal Year | Total Assets | YoY Change |
|---|---|---|
| 2025 | $582.98M | -26.4% |
| 2024 | $792.34M | +70.2% |
| 2023 | $465.63M | +32.0% |
| 2022 | $352.74M | -20.7% |
| 2021 | $444.65M | +88.5% |
| 2020 | $235.84M | +91.8% |
| 2019 | $122.93M | -21.1% |
| 2018 | $155.81M | -50.6% |
| 2017 | $315.62M | -17.7% |
| 2016 | $383.36M | +13.6% |
| 2015 | $337.58M | +36.1% |
| 2014 | $248.01M | -28.5% |
| 2013 | $347.10M | +176.5% |
| 2012 | $125.54M | +28.1% |
| 2011 | $97.99M | -10.9% |
| 2010 | $109.94M | — |
Quarterly Total Assets
| Quarter Ending | Total Assets | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $648.44M | -21.2% | -6.4% |
| June 30, 2025 | $692.41M | -18.1% | -6.4% |
| March 31, 2025 | $739.47M | -14.9% | -6.7% |
| December 31, 2024 | $792.34M | +70.2% | -3.7% |
| September 30, 2024 | $823.18M | +193.7% | -2.6% |
| June 30, 2024 | $845.59M | +182.5% | -2.7% |
| March 31, 2024 | $868.85M | +167.7% | +86.6% |
| December 31, 2023 | $465.63M | +32.0% | +66.1% |
- Celldex Therapeutics, Inc. showed a decrease of -26.4% in Total Assets compared to the prior fiscal year.
- Over the 2010–2025 period, Celldex Therapeutics, Inc.’s total assets has grown by 430.3% (from $109.94 million to $582.98 million).
- The most recent figure is from Celldex Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: